Latest Breaking News On - Roland chen - Page 3 : vimarsana.com

Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis

Designation is based on results from the progressive pulmonary fibrosis cohort of the Phase 2 study assessing the safety and efficacy of BMS-986278 treatment versus placebo ...

Novel Antifibrotic Designated Breakthrough Therapy for Progressive Pulmonary Fibrosis

The FDA has granted Breakthrough Therapy designation to BMS-986278, an investigational LPA1 antagonist, for progressive pulmonary fibrosis.

Ozanimod treatment linked to functional, cognitive improvements, reduced lesions in MS

Relapse, disease worsening similar with ozanimod treatment in relapsing MS

Data show Sotyktu maintains treatment outcomes for plaque psoriasis at 3 years

Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up t

Clinical response was maintained at 73.2% for Psoriasis Area and Severity Index (PASI) 75 with three years of continuous Sotyktu treatment in the POETYK PSO long-term extension trialSotyktu demonstrated a consistent safety profile with no increases in adverse events or serious adverse events and no emergence of any...

Bristol-Myers Squibb (BMY) Reports Sotyktu Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Bristol-Myers Squibb (BMY) Presents New Zeposia Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

BMS shares positive long-term data for Zeposia in relapsing multiple sclerosis